抗腫瘤壞死因子配體超家族成員13(TNFSF13)多克隆抗體
Anti-Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13) Polyclonal Antibody
CD256; APRIL; TALL2; TRDL1; ZTNF2; A Proliferation Inducing Ligand; TNF And APOL Related Leukocyte Expressed Ligand 2; TNF-Related Death Ligand 1
- 編號FAB750Bo01
- 物種Bos taurus; Bovine (Cattle，牛)相同的名稱，不同的物種。
- 效價-
- Ig類型IgG
- 純化方式抗原特異性親和純化
- 標記物無標記物
- 激發(fā)波長-
- 單次使用量1-5 μl
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 且適物種Homo sapiens (Human，人)
- 應用FCM
- 下載英文說明書 中文說明書
- 規(guī)格25test50test100test200test500test
- 價格¥ 720¥ 1200¥ 1920¥ 2400¥ 4200
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
Human Hela cell line was fixed with 2% paraformaldehyde (10 min) , permeabilised with 0.1% BSA-Triton X-100,then stained with 20μg/ml rabbit Anti-bovine TNFSF13 Polyclonal Antibody (Catalog FAB750Bo01, red histogram) or Isotype control antibody (Catalog IS067-Rb01, green histogram), followed by 1μg/ml FITC-conjugated Anti-rabbit IgG Secondary Antibody (Catalog SAA544Rb18).
通過ISO 9001、ISO 13485質量體系認證
用法
For flow cytometry, the suggested use of this reagent is 1-5 μl per 10^6 cells in 100 μl volume.
Optimal working dilutions could be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過一年。避免反復凍融。
贈品
增值服務
相關產(chǎn)品
| 編號 | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPB750Bo01 | 腫瘤壞死因子配體超家族成員13(TNFSF13)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB750Bo01 | 腫瘤壞死因子配體超家族成員13(TNFSF13)多克隆抗體 | WB; IHC; ICC; IP. |
| FAB750Bo01 | 抗腫瘤壞死因子配體超家族成員13(TNFSF13)多克隆抗體 | FCM |
參考文獻
| 雜志 | 參考文獻 |
| Journal of Critical Care | Serum concentrations of A Proliferation-Inducing Ligand (APRIL) are elevated in sepsis and predict mortality in critically ill patients[PubMed: 23337484] |
| Haematologica | Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells[Pubmed: 30819903] |
| Gene | A Significant Decrease of BAFF, APRIL, and BAFF Receptors Following Mesenchymal Stem Cell Transplantation in Patients with Refractory Rheumatoid Arthritis[Pubmed: 31935514] |